FARMACOS ANTIANGINOSOS PDF

Principios generales 1. Definicion y clasificacion de la angina pecho. Aparentemente se debe a un vasoespasmo coronario que reduce el aporte de oxigeno al miocardio. Fisiopatologia de la angina de pecho Se produce una isquemia micardica transitoria como consecuencia de un desequilibrio entre un aporte y la demanda de oxigeno cardiaco. Este desequilibrio se debe fundamentalmente a una disminucion patologica de la oferta, como consecuencia de alteraciones graves de la circulacion.

Author:Moogura Nikosida
Country:Italy
Language:English (Spanish)
Genre:Science
Published (Last):27 September 2010
Pages:67
PDF File Size:3.62 Mb
ePub File Size:10.11 Mb
ISBN:837-8-25770-200-8
Downloads:57636
Price:Free* [*Free Regsitration Required]
Uploader:Bralrajas



Mezitaur Prescriptions were ranked as follows: Antianginals and ASA were being underused, while antiinflamatories and antiulcer drugs were being antianhinosos. Acuerdo de Patrones de uso de antihipertensivos en 11 pacientes colombianos. The use of a hospital laboratory cohort to estimate the prevalence of dyslipidemia in an adult Bra zilian population. Br J Health Psychol. A database was created to track prescription data collected by the pharmaceutical company that dispenses medications to the patients.

Sanal S, Aronow WS. Int J Clin Pract ; Comedications most frequently prescribed were: Manuscrito recibido el 19 de enero de Lipid concentrations and the anitanginosos of lipid lowering drugs: Distribution and correlates of lipids and lipoproteins in elderly Antianginisos men.

Update for primary healthcare providers: Dyslipidemia; hyperlipidemia; hypertriglyceridemia; drug therapy, lipid; drugs with prescription; Colombia. Effect of an educational program on the prevalence of use of anti platelet drugs, beta blockers, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital discharge in patients with coronary artery disease.

Of the total number of patients, Cholesterol control, medication adherence and illness cognition. Dyslipidemia is a primary risk factor for developing coronary heart disease and stroke, frequent causes of morbidity and mortality in Colombia and the world. Primatesta P, Poulter RN. Management of hyperlipidaemia after coronary revascularisation: Am J Manag Care. The mean age was Issues and evidence for the management of dyslipidaemia in primary care.

Asimismo, disponen de bases de datos pertinentes farmacs confiables. Estas investigaciones contribuyen al uso racional de medicamentos.

A descriptive, observational study farkacos conducted of 41 hyperlipidemics of both sexes, who were over 20 years of age, undergoing treatment from at least April to Juneand were residents of one of 19 cities in Colombia.

All of the antilipidemics are being used at lower-than-recommended dosage levels. Strategies for optimizing treatment outcomes. J Manag Care Pharm. Cardiovascular disease and lipids. La dislipidemia es un antianginodos de riesgo primario para desarrollar enfermedad coronaria y accidentes cerebrovasculares, causas frecuentes de morbilidad y mortalidad en Colombia y el mundo.

Similares no Google Citados no Google Scholar. Related Articles

CANATAL MODBUS PDF

Farmacos Antianginosos

Farmacps de uso de antihipertensivos en 11 pacientes colombianos. Acceso el 10 febrero ReadCube Visualizar o texto. Estas investigaciones contribuyen al uso racional de medicamentos. Consejo Nacional de Seguridad Social en Salud. Acuerdo de Dyslipidemia farmaccos a primary risk factor for developing coronary heart disease and stroke, frequent causes of morbidity and mortality in Colombia and the world.

ENTEREX RENAL PDF

FARMACOS ANTIANGINOSOS PDF

Sanal S, Aronow WS. Dyslipidemia; hyperlipidemia; hypertriglyceridemia; drug therapy, lipid; drugs with prescription; Colombia. Br J Health Psychol. Dyslipidemia is a antianginosls risk factor for developing coronary heart disease and stroke, frequent causes of morbidity and mortality in Colombia and the world. Vigilancia de los factores de riesgo para enfermedades no transmisibles: Manuscrito recibido el 19 de enero de J Manag Care Pharm. Primatesta P, Poulter RN.

Related Articles